|Day Low/High||200.08 / 212.76|
|52 Wk Low/High||117.34 / 497.49|
Expect more fiscal and monetary support and don't expect a full return to previous economic activity for quite some time.
Headlines questioning phase-one trial data by Moderna spurred late selling as this market is still a bear.
So, let me get this straight. Moderna rushes to do a secondary last night even though they don't need the money yet. To me, if the vaccine works and they need to produce it in quantity, the stock will be many multiples higher than today -- and there...
Remarkable story about the vaccine czar and Moderna .
* I don't yearn or expect another yesterday, today. * Let it be... "Yesterday All my troubles seemed so far away Now it looks as though they're here to stay Oh, I believe in yesterday Suddenly I'm not half the man I used to be There's a shadow hangi...
Watching Moderna, Microsoft and FedEx as risk continues to be a central market theme, despite Monday's rally.
Let's step back and look at this market that has abandoned all sorts of safety and went all in on the stocks of companies based on the Fed's words and a promising Moderna study.
I'm long this name, as I am several of the others involved. Will I add on a day like this?
* The bears' skepticism (and cautious market positioning) coupled with their collective cynicism towards medical and scientific innovation, and the inevitability of the curve's flattening along with an "all in" Fed, have fueled the market recovery f...
Jerome Powell hit the airwaves with some words of caution and comfort. Nvidia is running into earnings.
GE's problem can be summarized in one sentence: The company is burning cash.
Trump administration taps former GlaxoSmithKline exec as head of vaccine task force, and how I'm playing Walmart and Datadog.
There are simply an immense number of health and technology and safety companies coupled with businesses that thrive when you have to stay home.
Thursday's rally was sparked by news that Moderna's Covid-19 vaccine candidate is moving to Phase II testing.
I get this rally -- it's based on more than a breaking branch this time, but there are still many uncertainties.
I'm staying long this name, and I'm staying long PFE and JNJ, and I'm staying long GILD and ABT. You know why? Because I'm optimistic.
As Treasury heads for longer-dated issuance and names like PTON run higher on earnings, selloffs late in the trading day continue.
PFE is collaborating with German drugmaker BioNTech in the effort to find a well tolerated, effective vaccine.
The market sold off on Thursday after close as big hitters, including Amazon, reported earnings.
There was a mild increase in trading volume at the New York Stock Exchange, but it was a rotational shift.
It's imperative that people get back to work, so we have this great compromise -- let's see how it might play out.
Money movers are not buying protection for individual names, but they are starting to bet against the market en masse, while the Russell 2000 ran up 4% on Monday.
Trading volumes dropping on major indexes, U.K. teams begin human trials on a Covid-19 vaccine, and the U.S. Senate wants another stimulus package addition.
A look at some names that Robinhood brokerage CEO Tenev tells us young people are buying.
Will tech continue to trend toward leadership? Who among us can remember when it has not?
Welcome to the new era. Social distancing is not without risks, but it is as good as it gets.
The Smartest Trader has made some important moves today. On gold, he cut his futures position by 60% a few hours ago and then repurchased one third back. He doesn't like the look of the precious metal (again he mentioned "getting tired") - and will ...
Let's take a look at the charts and indicators.
The rise in equity futures pricing was born of optimism from the president's task force draft guideline on reopening parts of the U.S. economy and Gilead Sciences' somewhat positive results on its remdisivir anti-viral treatment.